Ignite Creation Date:
2024-10-25 @ 7:49 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06581497
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
None
First Post:
2024-08-30
Brief Title:
ICIs With and Without MWA in Advanced Hepatocellular Carcinoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Comparing the Efficacy of ICIs With and Without MWA in Advanced Hepatocellular Carcinoma in Real-World Clinical Practice
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IMI-aHCC
Brief Summary:
Immunotherapy has become the main treatment recommendation for HCC MWA treatment induces peripheral immune response which may enhance the effectiveness of immunotherapy for advanced HCC This study aims to compare the efficacy and safety of ICIs combined with MWA compared to ICIs alone
The study will compare two groups ICIs and ICIsMWA Main objectives OS PFS Secondary objectives CR PRSDPDORRDCRAEs This study addresses the efficacy and safety of using ICIs in combination with MWA compared to ICIs alone for advanced HCC patients
Our study aims to evaluate the necessity of immunotherapy combined with targeted drugs or microwave ablation in patients with advanced hepatocellular carcinoma in the real world providing relevant clinical data for the treatment selection of HCC patients
The study will compare two groups ICIs and ICIsMWA Main objectives OS PFS Secondary objectives CR PRSDPDORRDCRAEs This study addresses the efficacy and safety of using ICIs in combination with MWA compared to ICIs alone for advanced HCC patients
Our study aims to evaluate the necessity of immunotherapy combined with targeted drugs or microwave ablation in patients with advanced hepatocellular carcinoma in the real world providing relevant clinical data for the treatment selection of HCC patients
Detailed Description:
Research Title Comparing the Efficacy of ICIs with and without MWA in Advanced Hepatocellular Carcinoma in Real Clinical Practice Background Immunotherapy has become the main treatment recommendation for cancer Ablation therapy induces peripheral immune response which may enhance the effectiveness of immunotherapy in patients with advanced hepatocellular carcinoma HCC
Main objectives OS PFS Secondary objectives CR PRSDPDORRDCRAEs Research Design This is a single center retrospective cohort study This study addresses the efficacy and safety of using ICIs in combination with MWA compared to ICIs alone for advanced HCC patients
Meaning Our study aims to evaluate the necessity of immunotherapy combined with targeted drugs or microwave ablation in patients with advanced hepatocellular carcinoma in the real world providing relevant clinical data for the treatment selection of HCC patients
Innovation The innovation of this paper lies in the first verification of the efficacy and safety of microwave ablation MWA combined with immune checkpoint inhibitors ICIs in the treatment of advanced hepatocellular carcinoma HCC patients
Expected results The innovation of this paper lies in the first validation of the significant efficacy of microwave ablation MWA combined with immune checkpoint inhibitors ICIs in the treatment of advanced hepatocellular carcinoma HCC patients significantly improving overall survival OS and progression free survival PFS as well as objective response rate ORR and disease control rate DCR
Conclusion Our study aims to evaluate the necessity of immunotherapy combined with targeted drugs or microwave ablation in patients with advanced hepatocellular carcinoma in the real world providing relevant clinical data for the treatment selection of HCC patients
Main objectives OS PFS Secondary objectives CR PRSDPDORRDCRAEs Research Design This is a single center retrospective cohort study This study addresses the efficacy and safety of using ICIs in combination with MWA compared to ICIs alone for advanced HCC patients
Meaning Our study aims to evaluate the necessity of immunotherapy combined with targeted drugs or microwave ablation in patients with advanced hepatocellular carcinoma in the real world providing relevant clinical data for the treatment selection of HCC patients
Innovation The innovation of this paper lies in the first verification of the efficacy and safety of microwave ablation MWA combined with immune checkpoint inhibitors ICIs in the treatment of advanced hepatocellular carcinoma HCC patients
Expected results The innovation of this paper lies in the first validation of the significant efficacy of microwave ablation MWA combined with immune checkpoint inhibitors ICIs in the treatment of advanced hepatocellular carcinoma HCC patients significantly improving overall survival OS and progression free survival PFS as well as objective response rate ORR and disease control rate DCR
Conclusion Our study aims to evaluate the necessity of immunotherapy combined with targeted drugs or microwave ablation in patients with advanced hepatocellular carcinoma in the real world providing relevant clinical data for the treatment selection of HCC patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None